Syncope during boceprevir treatment in hepatitis C.

Dear Editor:Recently, the standard of care (SoC) of chronichepatitis C virus (HCV) infection has changed, andHCV treatment has entered a new era with theintroduction of direct-acting antiviral agents(DAAs). Combination therapy with pegylated inter-feron (pegIFN) and ribavirin (RBV) and the twofirst generation NS3/4A protease inhibitors (PI) –te-laprevir (TVR) and boceprevir (BOC)– has beenapproved in many countries.